news
Eplontersen trial shows mixed heart benefit with combo therapy
A Nature Medicine secondary analysis of a phase 3 trial (NCT04136171) on Eplontersen for transthyretin amyloid cardiomyopathy found adding the drug improved nerve function but showed mixed results for heart health when patients were already on other stabilizers. The 144-patient study highlighted challenges in assessing new treatments for complex conditions, especially when layering therapies.
A Nature Medicine secondary analysis of a phase 3 trial (NCT04136171) on Eplontersen for transthyretin amyloid cardiomyopathy found adding the drug improved nerve function but showed mixed results for heart health when patients were already on other stabilizers. The 144-patient study highlighted challenges in assessing new treatments for complex conditions, especially when layering therapies.
The architecture take
So, you've got this new drug, Eplontersen, meant to help with a tricky heart condition where proteins misfold and gum things up. The original trial showed it helped nerves, which is good. But this secondary analysis tried to figure out if it still helped the heart if you were already on other heart meds. It didn't quite land the punch I'd hoped for on the cardiac side; some metrics improved, some didn't, others actually got worse. It's a reminder that bodies aren't simple. You can’t just add a new variable to an already-treated system and expect a linear upgrade. It makes me wonder if we're chasing too many silver bullets instead of understanding the system first. This trial just proves that 'more' isn't always 'better' when it comes to regulating the body.